Literature DB >> 16127051

Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.

Alok Mulky1, John C Kappes.   

Abstract

The reverse transcriptase (RT) of all retroviruses is required for synthesis of the viral DNA genome. The human immunodeficiency virus type 1 (HIV-1) RT exists as a heterodimer made up of 51-kDa and 66-kDa subunits. The crystal structure and in vitro biochemical analyses indicate that the p66 subunit of RT is primarily responsible for the enzyme's polymerase and RNase H activities. Since both the p51 and p66 subunits are generated from the same coding region, as part of the Pr160(Gag-Pol) precursor protein, there are inherent limitations for studying subunit-specific function with intact provirus in a virologically relevant context. Our lab has recently described a novel system for studying the RT heterodimer (p51/p66) wherein a LTR-vpr-p51-IRES-p66 expression cassette provided in trans to an RT-deleted HIV-1 genome allows precise molecular analysis of the RT heterodimer. In this report, we describe in detail the specific approaches, alternative strategies, and pitfalls that may affect the application of this novel assay for analyzing RT subunit structure/function in infectious virions and human target cells. The ability to study HIV-1 RT subunit structure/function in a physiologically relevant context will advance our understanding of both RT and the process of reverse transcription. The study of antiretroviral drugs in a subunit-specific virologic context should provide new insights into drug resistance and viral fitness. Finally, we anticipate that this approach will help elucidate determinants that mediate p51-p66 subunit interactions, which is essential for structure-based drug design targeting RT heterodimerization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127051      PMCID: PMC1195396          DOI: 10.1128/AAC.49.9.3762-3769.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains.

Authors:  M C Morris; V Robert-Hebmann; L Chaloin; J Mery; F Heitz; C Devaux; R S Goody; G Divita
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

Review 2.  Update of the drug resistance mutations in HIV-1: 2004.

Authors:  Victoria A Johnson; Francoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Richard T D'Aquila; Lisa M Demeter; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas D Richman
Journal:  Top HIV Med       Date:  2004 Oct-Nov

3.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.

Authors:  Gilda Tachedjian; Katie L Moore; Stephen P Goff; Nicolas Sluis-Cremer
Journal:  FEBS Lett       Date:  2005-01-17       Impact factor: 4.124

5.  Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing.

Authors:  Y Quan; P Inouye; C Liang; L Rong; M Götte; M A Wainberg
Journal:  J Biol Chem       Date:  1998-08-21       Impact factor: 5.157

6.  Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.

Authors:  X Wu; H Liu; H Xiao; J A Conway; E Hehl; G V Kalpana; V Prasad; J C Kappes
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

9.  Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif.

Authors:  D Harris; P N Yadav; V N Pandey
Journal:  Biochemistry       Date:  1998-07-07       Impact factor: 3.162

10.  Nucleotide specificity of HIV-1 reverse transcriptases with amino acid substitutions affecting Ala-114.

Authors:  Clara E Cases-González; Luis Menéndez-Arias
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

View more
  3 in total

1.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

3.  The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis.

Authors:  David P Sargeant; Sandeep Deverasetty; Christy L Strong; Izua J Alaniz; Alexandria Bartlett; Nicholas R Brandon; Steven B Brooks; Frederick A Brown; Flaviona Bufi; Monika Chakarova; Roxanne P David; Karlyn M Dobritch; Horacio P Guerra; Michael W Hedden; Rma Kumra; Kelvy S Levitt; Kiran R Mathew; Ray Matti; Dorothea Q Maza; Sabyasachy Mistry; Nemanja Novakovic; Austin Pomerantz; Josue Portillo; Timothy F Rafalski; Viraj R Rathnayake; Noura Rezapour; Sarah Songao; Sean L Tuggle; Sandy Yousif; David I Dorsky; Martin R Schiller
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.